The Latest Cardiac and Vascular News
– Phase 3 ELEVATE UC 12 trial reached full enrollment; topline data expected Q1 2022 with ELEVATE UC 52 – Liquidity position at ~$1.0 billion as of June 30, 2021 to support continued pipeline progress PARK CITY, Utah–(BUSINESS WIRE)–Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported […]
PARK CITY, Utah–(BUSINESS WIRE)–Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Steven Schoch to the Company’s Board of Directors and as Chair of the Audit Committee. Mr. Schoch brings more than 20 years of financial and operational leadership and expertise across a range of areas in biopharmaceuticals, media, and […]
– Evaluating the safety, tolerability, and efficacy of intravenous (IV) temanogrel for cMVO in adult participants undergoing percutaneous coronary intervention (PCI) – Currently no FDA approved therapies indicated for the treatment of cMVO – Temanogrel was granted FDA Fast Track Designation for the treatment of cMVO PARK CITY, Utah–(BUSINESS WIRE)–Arena […]
– Improvement by two score levels to “A” following the Company’s 2021 ESG Report launch underscores Arena’s long-term commitment to ESG principles PARK CITY, Utah–(BUSINESS WIRE)–Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that as of 2021, Arena received an MSCI ESG Rating of “A.” MSCI ESG Research provides MSCI ESG Ratings […]
– Appoints Kevin R. Lind as President and Chief Executive Officer of Arena Neuroscience, Inc. – Appoints Laurie D. Stelzer as Executive Vice President and Chief Financial Officer of Arena – Expects to deliver up to eight major data readouts between 2020-21 and multiple INDs – Progressing first- or best-in-class […]
– APD418 currently in Phase 1 clinical investigation – data expected this year SAN DIEGO, Jan. 16, 2020 /PRNewswire/ — Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for APD418, a β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope, in development for the treatment of […]
